Pharmaceutical & Clinical Pharmacy Research Group (PCPRG)

Keyphrases

1. Realist Review 100%
2. Older People 83%
3. People with Dementia 65%
4. Severe Mental Illness 63%
5. Pharmacist 58%
6. Virtual Clinical Trials 56%
7. Pharmacokinetics 54%
8. Living with 53%
9. Community Pharmacy 52%
10. Realist Synthesis 51%
11. Program Theory 50%
12. Medication Management 50%
13. Medication Use 49%
14. Primary Care 49%
15. Medication Adherence 46%
16. Medicines Optimisation 42%
17. Pediatric 42%
18. Attention Deficit Hyperactivity Disorder 41%
19. Sleep Disturbance 37%
20. Rapid Realist Review 37%
21. Orally Disintegrating Tablet 37%
22. Over-the-counter 34%
23. Prescription-only 34%
24. Dementia 34%
25. What Works 34%
26. During Pregnancy 33%
27. Service Users 31%
28. Substance Misuse Services 30%
29. Pharmacy 29%
30. Mixed Methods Evaluation 29%
31. Z-drugs 29%
32. Realist 28%
33. Antipsychotics 28%
34. Pharmacokinetic Modeling 28%
35. Plasma Concentration 28%
36. Initial Program Theory 28%
37. Drug Interactions 28%
38. MEDLINE 27%
39. Solid Oral Dosage Forms 27%
40. Behaviours That Challenge 27%
41. Mild Cognitive Impairment 27%
42. Treatment Services 27%
43. Oxadiazole 27%
44. Amino Acids 27%
45. Dosage Forms 27%
46. Precision Dosing 27%
47. Mental Health 27%
48. Medication Misuse 25%
49. Non-pharmaceutical Interventions 24%
50. Confidence Interval 24%
51. Clinical Trials 23%
52. Realist Evaluation 23%
53. Care Homes 23%
54. Community Pharmacists 22%
55. Context-mechanism-outcome Configurations 22%
56. Prospero 22%
57. Antipsychotic-induced Weight Gain 22%
58. Cognitive Function 22%
59. Clinical Pharmacist 22%
60. Age-appropriate 22%
61. Pharmacy Practice 21%
62. Medication-taking 21%
63. Cognitive Decline 21%
64. Lived Experience 21%
65. General Practice 21%
66. Population Groups 21%
67. Family Caregivers 20%
68. ADHD Medication 20%
69. Challenging Behaviour 20%
70. Realist Research 20%
71. Hong Kong 20%
72. Healthcare Professionals 20%
73. Antidepressants 20%
74. Response to COVID-19 20%
75. Physiologically-based Pharmacokinetic Model 19%
76. Formulation Approaches 19%
77. Older Population 19%
78. Swallowability 19%
79. Inclusion Criteria 19%
80. Acidic Amino Acid 18%
81. Pharmacist Attitudes 18%
82. Cardiometabolic Risk 18%
83. COVID-19 18%
84. Metabolic Syndrome 18%
85. Dry Particle Coating 18%
86. People with Intellectual Disabilities 18%
87. Ciprofloxacin 18%
88. MPharm 18%
89. Sexual Violence 18%
90. Rifampicin 18%
91. 2(5H)-furanone 18%
92. Systematic Literature Review 18%
93. Osteoporosis Treatment 18%
94. Supporting Patients 18%
95. Osteoporosis 18%
96. Primary Diagnosis 18%
97. Meta-analysis 18%
98. Australia 18%
99. Primary Care Management 18%
100. Cancer Population 18%